Difference Between Carnitine and L-Carnitine
In clinical practice, the terms "carnitine" and "L-carnitine" are used interchangeably because L-carnitine is the only biologically active and therapeutically useful form of carnitine. 1
Stereochemistry and Biological Activity
L-carnitine is the naturally occurring, biologically active stereoisomer, while D-carnitine is its optical mirror image that lacks therapeutic benefit and may cause harm. 2
- Carnitine exists in three forms: L-carnitine (the active form), D-carnitine (the inactive/toxic form), and DL-carnitine (a racemic mixture of both). 2
- When clinicians or guidelines refer to "carnitine" without specifying the stereoisomer, they are referring to L-carnitine, as this is the only form with physiological function. 1, 3
- L-carnitine is synthesized endogenously in the kidney and liver from lysine and methionine, and healthy individuals—including strict vegetarians—produce sufficient amounts without requiring supplementation. 1, 3
Critical Distinction: Why D-Carnitine Should Be Avoided
D-carnitine is not only biologically inactive but actively interferes with L-carnitine function and causes toxicity. 2, 4
Mechanisms of D-Carnitine Toxicity:
- Competitive inhibition: D-carnitine competes with L-carnitine for intestinal absorption and renal tubular reabsorption, effectively depleting tissue levels of the active L-form. 2, 5
- Muscle depletion: After absorption, D-carnitine competitively depletes muscle L-carnitine levels, hindering fatty acid oxidation and energy formation. 2
- Clinical toxicity: D-carnitine causes myasthenia symptoms, cardiac arrhythmias, hepatic lipotoxicity, inflammation, oxidative stress, and apoptosis. 2, 4
- Metabolized as a xenobiotic: Unlike L-carnitine, D-carnitine is processed by the body as a foreign substance requiring detoxification pathways. 4
Clinical Evidence of Harm:
- Toxic effects have been documented in patients with renal failure on long-term hemodialysis, adriamycin cardiotoxicity, and stable angina pectoris. 2
- Animal studies demonstrate that D-carnitine feeding increases hepatic lipid deposition (from 11.97% to 20.21%), induces inflammation, and upregulates detoxification genes. 4
Practical Clinical Implications
Always prescribe or recommend L-carnitine specifically, never DL-carnitine (the racemic mixture). 2
- Despite 25 years of use in some countries, DL-carnitine supplementation should be avoided due to the competitive inhibition and toxicity of the D-isomer. 2
- Typical supplementation doses: 0.5–1 g/day for prevention in at-risk patients (prolonged parenteral nutrition, continuous renal replacement therapy); pharmacologic doses of 50–100 mg/kg/day (often 3 g/day in adults) for treatment of deficiency. 1
- Dietary sources: Red meat (beef, lamb) provides the highest L-carnitine concentrations, with levels increasing proportionally to meat redness; fish, poultry, and milk also contribute. 1, 3
Common Pitfall to Avoid
The critical error is assuming that "carnitine" supplements are equivalent regardless of stereoisomer. Always verify that any supplement or prescription specifies "L-carnitine" and not "DL-carnitine," as the racemic mixture contains 50% of the harmful D-isomer that will competitively inhibit the therapeutic effects of the L-form. 2, 4